Cytokinetics (CYTK) PT Lowered to $17 at H.C. Wainwright, Keeps 'Buy'; Focus Shifts to CK-107 and Then Omecamtiv Longer Term
Tweet Send to a Friend
H.C. Wainwright lowered its price target on Cytokinetics (NASDAQ: CYTK) to $17.00 (from $26.00) while maintaining a Buy rating after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
